31. 2021 Kawasaki Disease Guidelines
Listen now
Description
Today, in this episode, we’ll discuss the new “2021 Guideline for the Management of Kawasaki Disease”, the mysterious triggers that cause KD, the use of therapies such as IVIG, steroids, infliximab, anakinra, and compare multisystem inflammatory disease in children, or MIS-C (a condition very similar to Kawasaki Disease that is triggered by SARS COV-2). Joining us today is Dr. Mark Gorelik, lead Author of the “2021 Guideline for the Management of Kawasaki Disease”. He’s an assistant professor of pediatrics at the Columbia University Vagelos College of Physicians and Surgeons, is a pediatric rheumatologist, an allergist and immunologist. His research focuses on vasculitis, including Kawasaki disease, and on immune dysregulation.   
More Episodes
This week we discuss what a biosimilar is, why they’re causing such controversy and why they’ve taken seven years, since the FDA approved Amgevita, to come to market. We review the evidence behind the safety and efficacy of these drugs, the data from switching from a bio-originator to a...
Published 02/28/23
Published 02/14/23
This week, we have the distinct privilege to interview Dr. Dan Kaster, “The Father of Autio inflammatory Diseases”. His discoveries have taught us a great deal about how the immune system works, both in health and disease. His work has contributed to finding effective treatments for conditions...
Published 02/14/23